These findings may suggest that the lack of response to pembrolizumab in the other 11 OS patients might be due to the increase in TGF-β and Wnt signaling associated with an immunosuppressive tumor microenvironment with low T cell infiltration [64]. This evidence concerns the gene TGFB1 and neoplasm.